RMOC Best Value Biologic – Insulin Glargine Toolkit, consultation closed

Alison Alvey, Interim Co-Director, South West Medicines InformationPublished

A draft toolkit has been produced on Best value biologic – insulin glargine, on behalf of the RMOC system. Insulin glargine is the first medicine managed in primary care to have a biosimilar product, of which two are now available. The toolkit is intended to support clinicians in prescribing the best value biologic insulin glargine product. The toolkit includes the following:

  • Useful Links
  • Manufacturer Tools
  • Comparison of Product Specifications
  • Shared Experiences
  • Savings Tracker
  • Templates

This guidance has been developed with support from the NEL Commissioning Support Unit; with contributions from a range of stakeholders from various sectors in England with expertise in diabetes and endocrinology.

Previous versions of the toolkit were presented and discussed at the RMOC South January and September 2020 meetings. Following discussion and comments received from RMOC South members the document was further amended to produce the attached v8 toolkit.

This consultation is now closed. The consultation closed on 24th December.

Comments received used to shape the final draft submitted to the RMOC for approval.

If you have any questions please contact rmoc.south@nhs.net